Oslo, Norway, 1 August 2024: Mr. Jasper Kurth has assumed the position as CEO of Thor Medical with effect from 1 August, replacing Alf Bjørseth who will remain with the company as Senior Vice President & Strategic Advisor. Reference is made to the stock exchange announcement issued on 14 February regarding the Board’s engagement of Jasper Kurth as new CEO.

Mr. Kurth joins Thor Medical from Bayer Pharmaceuticals where he has held several positions, most recently as General Manager Radiology Nordics in Stockholm, and prior to that as Head of Business Operations & Strategy EMEA, Head of Sub-Region Western Europe Radiology (acting), and Chief of Staff and Head of Training Radiology Europe.

«I am very much looking forward to starting with Thor Medical and joining a team dedicated to revolutionizing healthcare and improving the lives of patients battling cancer. There is a strong and rapidly growing demand for thorium in radiotherapeutic applications, and we have many important milestones ahead in the coming months, quarters, and years,” says Jasper Kurth.

As previously announced, Dr. Alf Bjørseth will continue to support the company's client acquisition activities and technical development of a production facility for thorium-based alpha emitters at Herøya, Norway as Senior Vice President & Strategic Advisor.

Disclosure regulation

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

Contacts

• Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no

Attachments

• Download announcement as PDF.pdf